Meeting Highlights in Myelofibrosis from the ASH Annual Meeting

In this activity, three myelofibrosis experts discuss how new advances and research should be applied in clinical practice using updated data presented at the ASH annual meeting. Determining the optimal course of action following JAK inhibitor treatment failure/intolerance/disease progression is extremely difficult because there is no standard course of action. Fortunately, research is identifying new agents that appear to be effective either alone or when combined with ruxolitinib in newly diagnosed and/or progressing patients.